Related Experiment Video
Updated: Jul 29, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Transcatheter Left Atrial Appendage Closure
Gordon X Wong1, Gagan D Singh1
1University of California, Davis Medical Center, Sacramento, California, US.
Insights
Transcatheter left atrial appendage closure (LAAC) offers a safe alternative for patients with atrial fibrillation who cannot use blood thinners. Newer devices and ongoing trials are expanding its role in stroke prevention.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Atrial fibrillation (AF) is a common arrhythmia, increasing stroke risk.
- Many AF patients cannot tolerate oral anticoagulation (OAC) due to bleeding risks or contraindications.
- Transcatheter left atrial appendage closure (LAAC) emerged as an alternative to OAC for stroke risk reduction.
Purpose of the Study:
- To review current indications and evidence for transcatheter LAAC therapies.
- To discuss newer generation LAAC devices and their clinical trial data.
- To examine challenges in LAAC procedures and post-implantation care.
Main Methods:
- Review of contemporary clinical trials and evidence for transcatheter LAAC devices.
- Analysis of safety and efficacy data for devices like Watchman FLX and Amulet.
- Discussion of procedural imaging and antithrombotic regimen controversies.
Main Results:
- Transcatheter LAAC has demonstrated safety and efficacy in patients intolerant to OAC.
- Newer devices show promise, with large trials supporting their use.
- Ongoing research aims to define LAAC's role in broader AF populations.
Conclusions:
- Transcatheter LAAC is a viable alternative for stroke prevention in nonvalvular AF patients unsuitable for OAC.
- Further research, including ongoing trials, will clarify LAAC's potential as a first-line therapy.
- Addressing procedural and post-implantation challenges is key to optimizing LAAC outcomes.
Abstract:
Atrial fibrillation is the most common arrhythmia worldwide, placing a large population at risk for potentially disabling ischemic strokes, yet an estimated 50% of eligible patients cannot tolerate or are contraindicated to receive oral anticoagulation. Within the last 15 years, transcatheter options for left atrial appendage closure (LAAC) have provided a valuable alternative to chronic oral anticoagulation for reducing risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. With newer generation devices such as Watchman FLX and Amulet gaining approval from the US Food and Drug Administration in recent years, several large clinical trials have demonstrated the safety and efficacy of transcatheter LAAC in a population intolerant to systemic anticoagulation. In this contemporary review, we discuss the indications for transcatheter LAAC and the evidence evaluating the use of various device therapies currently available or in development. We also examine current unmet challenges in intraprocedural imaging and controversies in postimplantation antithrombotic regimens. Several ongoing seminal trials are hoping to clarify the role of transcatheter LAAC as a safe, first-line option for all patients with nonvalvular atrial fibrillation.
